anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
Circulating tumor cells (CTCs) are recognized as promising targets for liquid biopsy, which play an important role in early diagnosis and efficacy monitoring of cancer. However, due to the extreme scarcity of CTCs and partial size overlap between CTCs and white blood cells (WBCs), the separation and detection of CTCs from blood remain a big challenge. To address this issue, we fabricated a microfluidic chip by integrating a passive contraction-expansion array (CEA) inertial sorting zone and an active magnetophoresis zone with the trapezoidal groove and online coupled it with inductively coupled plasma mass spectrometry (ICP-MS) for rapid separation and precise detection of MCF-7 cells (as a model CTC) in blood samples. In the integrated microfluidic chip, most of the small-sized WBCs can be rapidly removed in the circular CEA inertial sorter, while the rest of the magnetically labeled WBCs can be further captured in the trapezoidal groove under the magnetic field. As a result, the rapid separation of MCF-7 cells from blood samples was achieved with an average recovery of 91.6% at a sample flow rate of 200 μL min-1. The developed online integrated inertial-magnetophoresis microfluidic chip-ICP-MS system has been applied for the detection of CTCs in real clinical blood samples with a fast analysis speed (5 min per 1 mL blood). CTCs were detected in all 24 blood samples from patients with different types of cancer, exhibiting excellent application potential in clinical diagnosis.
Chronic Kidney Disease (CKD) is becoming one of the major causes of morbidity and mortalities in 21st century. We have developed a bioengineered cellulosic paper device for the quantification of albumin (ALB) in physiological samples. The paper surface was activated and antibodies specific to target biomarker was immobilized on engineered paper surface. Every step after modification was characterized by FTIR, XPS, SPM and optical analysis. Further, the device model was designed using CAD file, and a 3-D cascade device was fabricated with in-built constant light source to provide proper and controlled environment for in-situ image analysis. After adding the sample on the bioengineered paper, the antigen-antibody reaction takes place, after that addition of dye results in change of color from yellow to blueish-green within 40 s. An optical method was employed for the analysis of the images by recognizing the specific area and the color intensity. Additionally, the immunosensor specificity was evaluated on number of molecules that are usually found in the serum sample. The linear dynamic range of the developed immunosensor has been reported to be 1-60 mg/mL, covering the normal as well as clinical range of ALB in physiological samples with a detection limit of 0.049(±0.002) mg/mL. With good precision and recovery, the device was able to successfully determine the ALB concentrations in serum sample. The developed device has simple and user-friendly interface and it may also help diagnosing CKD in personalized settings.
<P>PROBLEM TO BE SOLVED: To provide a bARE composition which is stable in storage and has sequentially a long-term activity.  <P>SOLUTION: The composition contains a substantially integral bARE class protein and in one embodiment, the composition contains a stabilizer which comprises a charged amino acid or the analog thereof. In another embodiment, the stabilizer contains an arginine or a phosphoarginine which is present in an amount of approximately 100-400 mM. In a further embodiment, the composition contains an uncharged substance or the analog thereof or an amphoteric substance. The amphoteric substance is an amphoteric surfactant which comprises 3-(3-cholamidopropyl)-dimethylammonio-1-propanesulfonate (CHAPS).  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention discloses a traditional Chinese medicine oral liquid, in particular a traditional Chinese medicine oral liquid for treating cholecystitis and gallstones and a preparation method thereof. The traditional Chinese medicine oral liquid for treating cholecystitis and gallstones is characterized by comprising the following components: wine Coptis chinensis, wine Scutellaria baicalensis, wine rheum officinale, honeysuckle, desmodium, vinegar fried turmeric, elecampane, bran fried fructus aurantii, vinegary radix bupleuri, vinegary corydalis tuber, radix clematidis, fructus amomi, vinegar fried endothelium corneum gigeriae galli, burnt hawthorn, smoked plum, Lygodium japonicum, Codonopsis pilosula, bran fried Chinese yam, honey astragalus and pepper. The traditional Chinese medicine oral liquid is specially used for treating cholecystitis and gallstones, and properties of the material medicines are changed or alleviated by means of compatibility so that medicine with strong property are alleviated. The invention has obvious clinical efficacy, treats both principal and secondary aspect of disease and is safe and reliable and better exerts functions of medicines without damaging liver and kidney. The traditional Chinese medicine oral liquid has good taste, is convenient to take, beneficial to storage and can be taken by diabetics and hyperpietics safely. Totally 360 patients are treated and total effective rate reaches 98%.
To output appropriate support information about operation of a reception machine.SOLUTION: A reception machine 70 acquires attribute information (age) on a patient who operates an operation screen (Fig. 15(a)), and acquires reference time (reference operating time) required for operation of the patient at the same age. Moreover, the reception machine 70 identifies threshold values C, D on the basis of the reference operating time for the patient of the same age as the patient who operates the operation screen. Then, the reception machine 70 performs guidance display as shown in Fig. 15(b) when the operation by the patient is not performed even if the time since the operation screen was displayed exceeds the threshold value C, and notifies a responsible staff terminal as shown in Fig. 15(c) when the operation by the patient is not performed even if the time exceeds the threshold value D.SELECTED DRAWING: Figure 15
Derivs. of pyrido 2,3-d pyrimidine 5-thione of formula (I), in which X together with the C and N atoms attached forms a 5-6 member hetero-cyclic aromatic ring contg. O, N or S, for use in animal and esp. human health, are made by reacting derivs. of formula (II) with a reactant able to substitute an S atom for the carboxylic O atom, e.g. P2S5, under normal pressure in organic pressure at 75-150 deg. C.
PURPOSE: A novel peptide which suppresses angiotensin-converting enzyme is provided to substitute an artificial material for treating or preventing cardiovascular diseases and to be widely used in related industries. CONSTITUTION: A peptide or an acid addition salt thereof has one amino acid selected among sequence numbers 1-4. The peptide suppresses angiotensin-converting enzyme. A nucleotide encodes the peptide. A vector contains the nucleotide. A composition for preventing or treating cardiovascular diseases contains the peptide as an active ingredient.
The efficacy of ZUNVEYL is based upon 3 bioavailability studies in healthy adults comparing galantamine immediate-release tablets and galantamine extended-release capsules to ZUNVEYL [see Clinical Pharmacology (12.3)].

The effectiveness of galantamine as a treatment for Alzheimer's disease is demonstrated by the results of 5 randomized, double-blind, placebo-controlled clinical investigations in patients with probable Alzheimer's disease, 4 with the immediate-release tablet and 1 with the extendedrelease capsule [diagnosed by NINCDS-ADRDA criteria, with Mini-Mental State Examination scores that were ≥10 and ≤24]. Doses studied with the immediate-release tablet were 8-32 mg/day given as twice daily doses. In 3 of the 4 studies with the immediate-release tablet, patients were started on a low dose of 8 mg, then titrated weekly by 8 mg/day to 24 or 32 mg as assigned. In the fourth study (USA 4-week Dose Escalation Fixed-Dose Study) dose escalation of 8 mg/day occurred over 4-week intervals. The mean age of patients participating in these 4 galantamine trials was 75 years with a range of 41 to 100. Approximately 62% of patients were women and 38% were men. The racial distribution was White 94%, Black 3% and other races 3%. Two other studies examined a three times daily dosing regimen; these also showed or suggested benefit but did not suggest an advantage over twice daily dosing.
Rapid diagnosis of acute myocardial infarction (AMI) is crucial for optimal patient management. Accurate diagnosis and time of onset of an acute event can influence treatment plans, such as percutaneous coronary intervention (PCI). PCI is most beneficial within 3 hours of AMI onset. MicroRNAs (miRNAs) are promising biomarkers, with potential of early AMI diagnosis, since they are released before cell death and subsequent release of larger molecules [e.g., cardiac troponins (cTn)], and have greater sensitivity and stability in plasma versus cTn regardless of timing of AMI onset. However, miRNA-based AMI diagnosis can result in false positives due to miRNA content overlap between AMI and stable coronary artery disease (CAD). Accordingly, we explored the possibility of using a miRNA profile, rather than a single miRNA, to distinguish between CAD and AMI, as well as different stages following AMI onset. First we screened a library of 800 miRNA using plasma samples from 4 patient cohorts; no known CAD, CAD, ST-segment elevation myocardial infarction (STEMI) and STEMI followed by PCI, using Nanostring miRNA profiling technology. From this screening, based on machine learning SCAD and Lasso algorithms, we identified 9 biomarkers (miR-200b, miR-543, miR-331, miR-3605, miR-301a, miR-18a, miR-423, miR-142, and miR-132) that were differentially expressed in CAD, STEMI and STEMI-PCI and explored them to identify a miRNA profile for rapid and accurate AMI diagnosis. These 9 miRNAs were selected as the most frequently identified targets by SCAD and Lasso, as indicated in the "drum-plot" model in the machine learning approach. We used age-matched patient samples to validate selected 9 miRNA biomarkers using a multiplexed ion-exchange membrane-based miRNA sensor platform, which measures specific miRNAs, and cTn as a control, simultaneously as a point-of-care device. Findings from this study will inform timely and accurate diagnosis of AMI and its stages, which are essential for effective management and optimal patient outcomes.
PROBLEM TO BE SOLVED: To obtain a tissue sealant capable of promoting hemostasis and cure of wound of skin and internal organs, endodermis formation by a vascular protease, in-vitro adhesion activities of an animal cell such as an endothelial cell and a fibroblast, and adhesion and cohesion of platelets. SOLUTION: This tissue sealant is obtained by adding carboxymethylcellulose of a polyvalent carboxymethyl ether of a cellulose to a sealant containing a fibrin. The fibrin is formed by allowing a thrombin to act on a fibrinogen when using the fibrin. The carboxymethylcellulose includes its sodium salt. The carboxymethylcellulose has 1.0 substitution degree of carboxy group and contains 8.5 wt.% sodium salt. The carboxymethylcellulose is the one having a lower molecular weight caused by the irradiation of electron beam, and having 200-2,000 kDa molecular weight.
The lung cancer is caused by mutual association among Qi-stagnation, blood stasis and phlegm congealing due to insufficient healthy atmosphere and infection of pathogenic factors (six evils and seven emotions). The invention discloses a traditional Chinese medicine preparation for treating the lung cancer. The lung cancer drug is prepared by 41 bulk drugs of edible tulip, nux vomica, nidus vespae, cantharides, nightshade, sculellaria barbata, sargassum, kelp, codonopsis pilosula, astragalus membranaceus, rehmannia glutinosa, radix polygoni multiflori, rhizoma atractylodis macrocephalae, LiuQu, hawthorn, fructus aurantii, rhizoma cyperi, rhizoma curcumae longae and ground beeltle by a certain weight ratio. Edible tulip, Chinese blister beetle, nux vomica and short-pedicel aconite root are refined to directly fill in capsules; the rest drugs are decocted with water. The drug is drunk orally. The lung cancer drug enhances the healthy atmosphere, restrains the cancer cell, acts the effects of strengthening healthy energy, eliminating evil and clearing toxin, and can obtain excellent curative effect for treating the lung cancer; if the treatment can be persisted, the taboo is kept and the horrible mentality of fearing death is discarded, the cure rate is higher.
The iv. bolus of UFH (100Units/kg) will be given immediately after TSP, defined as the introduction of transseptal sheath into the left atrium.
Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
PROBLEM TO BE SOLVED: To obtain a new compound having excellent testosterone-5α-reductase inhibiting action and useful for prevention and curing of prostatomegaly. SOLUTION: The objective compound k4610422 is expressed by the formula and has following properties; character: white powder; molecular formula: C19 H26 O2 ; molecular weight: 286; solubility: soluble in methanol, ethanol, acetone, dimethyl sulfoxide, benzene, chloroform, diethyl ether and ethyl acetate, insoluble in water; color reaction: positive to sulfuric acid and iodo. The compound of the formula is obtained by culturing a k4610422 producing bacterium, e.g. Streptosporangium sp. SANK62195 stock belonging to genus Streptosporangium by a shake-culturing, etc., in a medium of pH5-8 under an aerobic condition, extracting by using an organic solvent and purifying.  A testosterone-5α-reductase inhibitor is prepared by containing the compound of the formula as an active component, and an administrating amount of the inhibitor is 1-2,000mg per 1 day for an adult in a case of oral administration and 0.1-400mg in a case of intravenous administration.
The proposed study investigates safety and efficacy of a new topical vitamin D3 compound. The purpose of this Phase 1 trial is to determine whether topical application makes Vitamin D bioavailable to the systemic circulation in sufficient quantities to treat hypovitaminosis D. The study will assess the change in serum 25-hydroxy (25-OH) vitamin D concentrations following 3 doses of 100,000 IU or 3 doses of 300,000 IU of topical vitamin D3 ointment in volunteers with vitamin D deficiency. Adults with serum 25-OH vitamin D concentrations of \< 20 ng/ml will receive a total of 300,000 IU or 900,000 IU in divided doses of topical vitamin D once per week for three weeks. Two 0.75 ml applicators of ointment will be applied to each upper arm (50,000 IU or 150,000 IU per arm) by study staff. Blood will be drawn at baseline prior to the first dose (Day 0) and on Days 7, 14, and 21. Total serum 25-OH vitamin D will be assayed at each draw. Parathyroid hormone, a measure of clinical effects of low vitamin D levels, will be checked at baseline and on day 21. Serum albumin adjusted calcium levels will be checked with each draw to check for possible effects of too much vitamin D absorption. The study will determine whether the topical application of Vitamin D ointment is able to correct existing vitamin D deficiency.
Carcinogenicity studies have not been conducted with capivasertib. 

Capivasertib was genotoxic in the in vivo rat bone marrow micronucleus assay through an aneugenic mechanism. Capivasertib was not mutagenic in vitro in a bacterial reverse mutation (Ames) assay or mouse lymphoma gene mutation assay. 

In repeat-dose toxicity studies up to 26 weeks duration in rats and 39 weeks duration in dogs, tubular degeneration in the testes and cellular debris in the epididymides were observed at oral capivasertib doses of 100 mg/kg/day in rats and 15 mg/kg/day in dogs (approximately 1 time the human exposure at the recommended dose of 400 mg twice daily based on AUC). In a male fertility study, capivasertib had no effect on fertility in male rats at oral doses up to 100 mg/kg/day following 10 weeks of treatment. Effects of capivasertib on female fertility have not been studied in animals.
The present disclosure relates to methods, systems and kits for the diagnosis, prognosis and the determination of cancer progression of cancer in a subject. The disclosure also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful subtyping classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.
Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
A new model of delivering family-based pediatric overweight treatment that decreases costs but sustains short- and long-term efficacy is needed. One possible opportunity for this is a peer intervention model in which families receiving professionally-led intervention then subsequently providing intervention to other families. In addition, peer interventionists' continued engagement in the behavior change process through providing intervention to others could improve their own long-term efficacy. The project begins with the standard approach of having professional interventionists provide family-based behavioral pediatric overweight treatment to overweight children and their parent (1st generation families; n=30). Subsequently, half of 1st generation families will be randomly assigned to serve as peer interventionists to other overweight parents and children (2nd generation families; n=30). The remaining 1st generation families will neither receive nor provide any additional treatment. This project aims to develop the peer intervention training and delivery and then to examine the feasibility and acceptability of the peer intervention. This project also aims to derive an estimate of the efficacy of peer intervention (receiving and providing) both at the end of receiving treatment and 6 months later, as well as the impact of providing intervention on peer interventionists' weight outcomes.
The present invention relates to a novel cell-based tumor vaccine platform. The present invention provides a method of modifying Antigen Presenting Cells (APCs) to present MHC class I and/or MHC class II peptides in the context of improved peptide presenting protein complexes to increase activation of the immune response in a patient. In the present invention, a vaccine platform based on MHC II mRNA dendritic cells was developed to activate CD4 in patients + T cells and enhance the anti-tumor response. The constant chain (Ii) is modified and the hapten CLIP is replaced with the MHC II binding peptide sequence of the tumour associated antigen. These chimeric MHC II constructs are presented by APC and induce tumor specificityCD4 + T cells proliferate. The invention provides constructs, proteins, nucleic acids, recombinant cells and medical uses of these products.
The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
<P>PROBLEM TO BE SOLVED: To occlude a selected blood vessel by using a material, which rapidly expands (does not expands more by elapsed time) upon extruding, for treating and occluding aneurysm.  <P>SOLUTION: The method includes a method of occluding a selected target site of the subject. The method includes a process to make access to a selected site and a process to administer a rapidly expanding composition to the selected site and occlude the site thereby. In a specific embodiment, the composition includes a foam body and collagen or two or more materials. A list of possible embodiments on expanding materials is disclosed. The method maybe used together with known antibiotics and biologically active substances.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE:To provide the subject remedy for vasospasm containing a dihydropyridine derivative with a specified structure as the active component and having a remarkable and long acting relief effect for vasospasm and low toxicity. CONSTITUTION:The objective remedy is obtained by blending a compound of formula I [R1-R3 are alkyl, cycloalkyl or alkoxyalkyl; R4 and R5 are H, halogen, nitro, halogenated alkyl, etc.; X is vinylene or azomethine; A is alkylene; B is -N(R6)2 or formula II (R6 and R7 are H, alkyl, aralkyl, etc.; Ar is aryl or pyridyl; n is 0.2)] or an acid addition salt thereof as the active component, adding conventional additives thereto and carrying out pharmaceutical preparation using the conventional method. The pharmaceutical preparation can be carried out in a form such as powder, granule, tablet, capsule or injection. The dosage is 0.05-20mg/kg body weight/day in case of oral administration and 0.1-300mug/kg body weight/day in case of intravenous injection.
INTRODUCTION: The relationship between thyroid function/homeostasis parameters and renal function has been extensively studied. However, the relationship between thyroid function and thyroid homeostasis parameters with albuminuria among elderly individuals remains unclear.
METHODS: The population was divided into an albuminuria group and a non-albuminuria group for baseline characteristic difference analysis. Multivariable logistic regression was used to test the association between thyroid function, and thyroid homeostasis parameters and albuminuria. The nonlinear relationship was explored with restricted cubic splines. Meanwhile, we investigated whether the relationship also existed in the diabetes and hypertension subgroups. Receiver operating characteristic (ROC) curves were used to assess the effectiveness of the indices.
RESULTS: FT4 and TFQIFT4 were positively correlated with albuminuria (OR = 1.12; 95% CI = 1.02-1.23, p = 0.02; OR = 1.79; 95% CI = 1.08-2.99, p = 0.03), and FT3/FT4 was negatively correlated with albuminuria (OR = 0.03; 95% CI = 0.00-0.26, p = 0.003). Additionally, the nonlinear relationship between FT3/FT4 as well as TSHI and albuminuria was approximately U-shaped. Similar results were observed in the hypertension subgroup but not in the diabetes subgroup. There was a U-shaped nonlinear relationship between FT3 and albuminuria in the diabetes group. In addition, FT3/FT4 performed better than TFQI, TT4RI, and TSHI in ROC analyses for albuminuria prediction.
CONCLUSION: FT4, TFQIFT4, and a low FT3/FT4 ratio were risk factors for albuminuria in euthyroid individuals over 60 years old. However, FT3 was more associated with albuminuria in the diabetes subgroup. TSH was not associated with albuminuria in any analysis. In our study, we attempted to provide more reasonable thyroid parameters and basis for evaluating patients with underlying albuminuria. FT3/FT4 may be used as a helpful indicator to predict albuminuria and provide novel ideas for the evaluation and treatment of albuminuria.